Genentech's oral weight loss drug shows promise; FDA denies accelerated approval for Agenus' cancer drug; Orexo's opioid overdose drug rejected again [The good, the bad, the ugly]

Off Script: A Pharma Manufacturing Podcast

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week:

The good — Genentech's oral weight loss drug shows promise
The bad — FDA denies accelerated approval for Agenus' cancer drug
The ugly — Orexo's opioid overdose drug rejected again